TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00839085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSE
Description: grape seed extract (100 mg/6h), PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vit C (Ascorbic Acid)
Description: Vit C 25 mg/ kg
Study: NCT03267797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Monouclear Cell
Description: Blood samples (20 mL) were taken from individual patients at the time of ovulation induction. Then PBMC were isolated and cultured (20-30 million cells) 48 hour at the presence of hCG (10IU/ml daily). Afterward,15-20 million PBMCs in 500 microlitres PBS were injected into the uterine cavity two days before embryo transfer (ET) using ET catheter.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Baffer Saline
Description: Only 500 microlitres PBS will be injected into the uterine cavity, instead of PBMCs, two days before embryo transfer (ET) using ET catheter.
Study: NCT01741207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcystein
Description: Active Comparator: N-acetylcystein receive N-acetylcystein in addition to standard treatment
Study: NCT00562146

Intervention type: PROCEDURE
Intervention: placement of spiral nasojejunal tube
Description: spiral nasojejunal tube will be placed after enrollment of the patients
Study: NCT03942029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154207 Tablet
Description: Administered orally as tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally as tablet
Study: NCT01506661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax (varicella zoster virus) vaccine
Description: Standard vaccination protocol for Zostavax will be utilized. 0.65 ml (19,400 plaque forming units) Zostavax will be administered subcutaneously once at the baseline visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zostavax (varicella zoster virus) vaccine
Description: Standard vaccination protocol for Zostavax will be utilized. 0.65 ml (19,400 plaque forming units) Zostavax will be administered subcutaneously once at the baseline visit
Study: NCT03483298

Intervention type: OTHER
Intervention: ICSI
Description: The cryopreserved pre-TESA ejaculate and TESA specimen will be thawed on the day of oocyte retrieval per protocol for ICSI
Study: NCT01392612

Intervention type: DRUG
Group type: OTHER
Intervention: erythropoietin
Description: Subjects received one single intravenous injection of epoetin alpha (Erypo®, rhEPO, Ortho Biotech/Division of Janssen-Cilag Ag, Bridgewater, New Jersey, US) at a dose of 300 Units per kg bodyweight. Blood was sampled at baseline and 4, 24, 48 and 72 hours after administration of rhEPO during a biosimilarity trial.
Study: NCT03484390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Study: NCT01403922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Tablet oral bid days 1 to 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Tablet oral bid days 1 to 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Tablet oral bid days 8 to 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Tablet oral bid days 8 to 14
Study: NCT03012490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRT-P or CRT-D standard remote monitoring
Description: standard for the control group: remote monitoring of ventricular rhythm disorders and technical parameters of the implanted system

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CRT-P or CRT-D standard remote monitoring
Description: standard for the control group: remote monitoring of ventricular rhythm disorders and technical parameters of the implanted system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRT-P or CRT-D full remote monitoring
Description: Full follow-up for the Active group: remote monitoring of ventricular rhythm disorders and technical parameters of the implanted system + supraventricular rhythm disorders, parameters related to heart failure, including symptoms and clinical signs of the patient
Study: NCT03484390

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Group
Study: NCT00826670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decolonization
Description: Colistin sulphate (50mg 4x/d PO) + Neomycin (250mg 4x/day PO) for 10 days~plus In the presence of urinary tract colonization choice of one of the following agents (according to susceptibility profile, creatinine clearance and individual contraindications) Nitrofurantoin (100mg 3x/day PO) or Norfloxacin (400mg 2x/day PO) for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Decolonization)
Description: Placebo
Study: NCT03012490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptoms and signs remote monitoring
Description: symptoms and clinical signs of the patient
Study: NCT01483885

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous Electric Nerve Stimulation
Description: Tens at 4Hz and 100 Hz will be delivered using TENS stimulator (Ibramed/Neurodyn-São Paulo, Brazil)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electric Nerve Stimulation
Description: Tens at 4Hz and 100 Hz will be delivered using TENS stimulator (Ibramed/Neurodyn-São Paulo, Brazil)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electric Nerve Stimulation
Description: Tens at 4Hz and 100 Hz will be delivered using TENS stimulator (Ibramed/Neurodyn-São Paulo, Brazil)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Interferential Current
Description: Interferential Current (IC) at 4Hz and 100 Hz will be delivered using IC stimulator (Ibramed/Neurodyn-São Paulo, Brazil)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential Current
Description: Interferential Current (IC) at 4Hz and 100 Hz will be delivered using IC stimulator (Ibramed/Neurodyn-São Paulo, Brazil)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential Current
Description: Interferential Current (IC) at 4Hz and 100 Hz will be delivered using IC stimulator (Ibramed/Neurodyn-São Paulo, Brazil)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Acupuncture
Description: Manual acupuncture will be delivered with sterile needles for each subject in the acupoint TA5 and CS6 localized in the dominant forearm.
Study: NCT03465787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone HCL 160 mg
Description: Lurasidone HCL 2 80mg tablets, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine XR 600 mg
Description: Quetiapine XR 2 300 mg tablets, QD
Study: NCT02929940

Intervention type: OTHER
Intervention: No intervention
Description: No Intervention, observational

Intervention type: OTHER
Intervention: No intervention
Description: No Intervention, observational

Intervention type: OTHER
Intervention: No intervention
Description: No Intervention, observational
Study: NCT02784821

Intervention type: OTHER
Group type: OTHER
Intervention: Stool samples
Description: Microbiome will be evaluated using infant's stool.

Intervention type: OTHER
Group type: OTHER
Intervention: Stool samples
Description: Microbiome will be evaluated using infant's stool.

Intervention type: OTHER
Group type: OTHER
Intervention: Stool samples
Description: Microbiome will be evaluated using infant's stool.

Intervention type: DRUG
Group type: OTHER
Intervention: Antibiotics
Description: Babies that are randomized to antibiotics receive therapy based on the clinical team's discretion.
Study: NCT03942029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally as tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally as tablet
Study: NCT02790788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone; hydrocortisone
Description: Methylprednisolone 40 mg during resuscitation and stress-dose hydrocortisone for postresuscitation shock

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Saline placebo during resuscitation and during the postresuscitation phase.
Study: NCT00397514

Intervention type: PROCEDURE
Intervention: Congenital Heart Surgery Patients
Description: undergoing either Biventricular (BiV) pacing or Right Ventricular (RV) Pacing
Study: NCT02352688

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Colorectal Geriatric Care
Study: NCT03830372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR Tier One
Description: 10 sessions of 20 minutes virtual terapeutic game~Thanks to using VR googles and the phenomenon of total immersion VR Tier One terapy game allows to completely separate the patient from the hospital environment and provides an intense visual, auditory and kinesthetic stimulation. Depending on the stage of therapy it can have a calming and mood-improving effect or it can motivate and cognitively activate the patient. The additional aim of the game is to help the patients regain their emotional balance, let them recognize their resources in order to bring them to power in the rehabilitation process and trigger the natural recovery mechanisms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 10 sessions of 20 minutes of Schultz Autogenic Training
Study: NCT00452556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate (Eligard®)
Description: 2.5 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate (Eligard®)
Description: 2.5 years

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiotherapy
Description: Standard sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate, followed by irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiotherapy
Description: Standard sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate, followed by irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiotherapy
Description: Experimental sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate last, irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)first

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiotherapy
Description: Experimental sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate last, irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)first
Study: NCT01828801

Intervention type: DEVICE
Intervention: Pinnacle Metal-on Metal
Description: All patients that are post-operative will have undergone total hip arthroplasty with the Pinnacle Metal-on-Metal device

Intervention type: DEVICE
Intervention: Pinnacle Metal-on Metal
Description: All patients that are post-operative will have undergone total hip arthroplasty with the Pinnacle Metal-on-Metal device
Study: NCT02929940

Intervention type: OTHER
Intervention: No intervention
Description: No Intervention, observational
Study: NCT04675996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INT-1B3
Description: 60-min i.v. infusions twice per week in 21-day cycles
Study: NCT04680819

Intervention type: DIETARY_SUPPLEMENT
Intervention: Anatolian Propolis
Description: Health workers who agree to participate in the study will be accepted as the study group, and healthcare professionals who do not agree to participate in the study will be considered as the control group. The study group will be asked to take 20 drops of Propolis drop form twice a day in the morning / evening, and the control group will not receive any treatment and both groups will be followed. In this process, patients diagnosed with COVID-19 will be determined. PCR test positivity taken from the throat for the diagnosis of COVID-19 will be accepted. The research will cover a period of 1 month. At the end of 1 month, patients diagnosed with COVID-19 in the study and control groups will be compared. Thus, the protective properties of Anatolian propolis will be determined.
Study: NCT03848949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evenup
Description: Orthotic which increases effective leg length.
Study: NCT01600196

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver resection plus Thrombectomy
Description: Liver resection plus Thrombectomy
Study: NCT03837093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILT101
Description: Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILT101
Description: Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILT101
Description: Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILT101
Description: Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks
Study: NCT03942029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole Tablet
Description: Administered orally as tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole Tablet
Description: Administered orally as tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole Tablet
Description: Administered orally as tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole Tablet
Description: Administered orally as tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole Tablet
Description: Administered orally as tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole Tablet
Description: Administered orally as tablet
Study: NCT01976403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Booklet
Description: The Pain Relief After Cardiac Surgery is originally a Canadian booklet. The booklet is further developed and modified for Norwegian patients
Study: NCT04104399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC101-D13H
Description: XC101-D13H supplied as 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplied as matching capsules
Study: NCT03604159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Extended Release
Description: XRB is available in dosage strengths of 100 mg/0.5 mL and 300 mg/1.5 mL buprenorphine. Each dose is provided in a prefilled syringe with a 19 gauge 5/8-inch needle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
Description: SLB is administered sublingually or buccally as a single daily dose. Medication should be prescribed in consideration of the frequency of visits. Provision of multiple refills is not advised in early treatment or without appropriate follow-up visits. After treatment induction and stabilization, the maintenance dose of SLB is generally in the range of 4mg/1mg buprenorphine/naloxone to 24mg/6mg buprenorphine/naloxone per day depending on the individual patient and clinical response.
Study: NCT04929782

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resin-based sealant
Description: Etching with 37% phosphoric acid for 30 s (i-GEL N, i-dental, Lithuania), rinsing for 30 s with air-water spray and drying with oil-free air for 15 s, resin sealant (Conceal F, SDI, Australia) application into the occlusal and buccal/palatal pits and fissures with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20s on each surface.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Giomer sealants
Description: Self-etch primer (BeautiSealant Primer, Shofu, Japan) application to the occlusal and buccal/palatal pits and fissures with fine microbrush and waiting for 5 s, homogenizing the bond layer with gentle air stream for 5 s, giomer sealant application (BeautiSealant Paste, Shofu, Japan) with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20 s on each surface.
Study: NCT02238509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
Study: NCT03941041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prenatal Yoga Course
Description: participation in a 12-week prenatal yoga course (optimally), 1 session in duration of 90 minutes per week
Study: NCT01678469

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Study: NCT03334994

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group:(Group B) connective tissue graft combined with immediate implant.
Description: Patients will be treated with connective tissue graft combined with immediate implant.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group:(Group B) connective tissue graft combined with immediate implant.
Description: Patients will be treated with connective tissue graft combined with immediate implant.
Study: NCT01047631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional circuit training and lifestyle counseling
Description: Tests are performed at the beginning, and repeated after 12 and 24 weeks:~* Measure general fitness levels such as walking, strength and balance.~* Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.~* Blood and urine tests and a heart ultrasound.~* Questionnaires \& activity measures.~Group assignment for 12 weeks:~-Exercise classes \& activity guidance: Twice-weekly class that focuses on exercises that are similar to daily activities, such as walking and carrying objects. Obtain customized information and education to help you exercise and follow a low salt diet.~Follow-up:~-Monthly phone calls during the 12 week follow up period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education and independent walking
Description: Tests are performed at the beginning, and repeated after 12 and 24 weeks.~* Measure general fitness levels such as walking, strength and balance.~* Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.~* Blood and urine tests and a heart ultrasound.~* Questionnaires \& activity measures.~Group assignment for 12 weeks:~-Health education and walking: Weekly health education classes covering general topics related to heart failure, like medications, diet and exercise. Receive a pedometer for an at-home walking program.~Follow-up:~-No follow up support
Study: NCT02554721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Study: NCT03935893

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: TIL are to be infused intravenously through a central vein catheter over 20-30 minutes followed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine + Cyclophosphamide combination
Description: Preparative lymphocyte depleting (immunosuppressive) combination regimen consisting of fludarabine and cyclophosphamide administered prior to TIL infusion.
Study: NCT00298792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment
Description: Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Treatment
Description: Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Description: Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral treatment
Description: Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety
Study: NCT02918006

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-A1.1
Description: Enteric coated oral vaccine tablet

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone®
Description: Fluzone Quadravalent (Fluzone®) influenza vaccine (QIV) suspension for intramuscular (IM) injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Placebo tablets similar in size, color and number to the active oral tablet vaccine drug product

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Tablets
Description: Placebo tablets similar in size, color and number to the active oral tablet vaccine drug product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Solution for Placebo IM Injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution for Placebo IM Injection